MX2009008561A - Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. - Google Patents
Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.Info
- Publication number
- MX2009008561A MX2009008561A MX2009008561A MX2009008561A MX2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A
- Authority
- MX
- Mexico
- Prior art keywords
- growth hormone
- cell proliferative
- proliferative disorders
- treating cell
- hormone secretagogues
- Prior art date
Links
- 239000003324 growth hormone secretagogue Substances 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90160907P | 2007-02-13 | 2007-02-13 | |
| PCT/US2008/001748 WO2008100448A2 (en) | 2007-02-13 | 2008-02-08 | Method of treating cell proliferative disorders using growth hormone secretagogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009008561A true MX2009008561A (es) | 2010-01-15 |
Family
ID=39690677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009008561A MX2009008561A (es) | 2007-02-13 | 2008-02-08 | Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080207640A1 (enExample) |
| EP (1) | EP2134341B1 (enExample) |
| JP (1) | JP2010518158A (enExample) |
| KR (1) | KR20090112720A (enExample) |
| CN (1) | CN101686966A (enExample) |
| AU (1) | AU2008216789A1 (enExample) |
| CA (1) | CA2677813A1 (enExample) |
| EA (1) | EA200970764A1 (enExample) |
| IL (1) | IL200367A0 (enExample) |
| MX (1) | MX2009008561A (enExample) |
| TW (1) | TWI450719B (enExample) |
| WO (1) | WO2008100448A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2011105611A1 (ja) * | 2010-02-26 | 2013-06-20 | ラクオリア創薬株式会社 | 悪液質を治療するためのグレリン受容体作動物質 |
| JO3353B1 (ar) | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
| CN108902893B (zh) | 2013-02-08 | 2022-02-25 | 通用磨坊公司 | 低钠食品 |
| KR102234319B1 (ko) * | 2014-09-04 | 2021-04-01 | 헬신 헬쓰케어 에스.에이. | 아나모렐린 기반의 의학적 치료 |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| JP7854809B2 (ja) | 2019-08-30 | 2026-05-07 | ヘルシン ヘルスケア ソシエテ アノニム | 安定性が改善されたアナモレリン錠剤の製造方法 |
| US12195458B2 (en) | 2019-12-02 | 2025-01-14 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
| WO2025104491A1 (en) | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2179597A1 (en) * | 1993-12-23 | 1995-06-29 | Nils Langeland Johansen | Compounds with growth hormone releasing properties |
| AU715856B2 (en) * | 1995-12-22 | 2000-02-10 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| EP1184370B1 (en) * | 1996-07-22 | 2005-09-14 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6566334B1 (en) * | 1997-02-06 | 2003-05-20 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Short amphipathic peptides with activity against bacteria and intracellular pathogens |
| US6286927B1 (en) * | 1997-12-25 | 2001-09-11 | Canon Kabushiki Kaisha | Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted |
| US6494563B2 (en) * | 1997-12-25 | 2002-12-17 | Canon Kabushiki Kaisha | Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted |
| US6083908A (en) * | 1998-01-16 | 2000-07-04 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6303620B1 (en) * | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6124263A (en) * | 1998-11-16 | 2000-09-26 | Asta Medica Ag | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| US6919315B1 (en) * | 1998-06-30 | 2005-07-19 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6566337B1 (en) * | 1998-11-03 | 2003-05-20 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| UA73530C2 (uk) * | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
| ATE446758T1 (de) * | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
| DE60140051D1 (de) * | 2000-06-07 | 2009-11-12 | Merck Serono Sa Coinsins | Menschliches wachstumshormon zur stimulierung der mobilisierung pluripotenter hämapoietischer stammzellen |
| EP1363898A4 (en) * | 2001-03-02 | 2004-12-08 | Bristol Myers Squibb Co | COMPOUNDS SUITABLE AS MODULATORS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| EP1312363A1 (en) * | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
| US7491695B2 (en) * | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| US20050261201A1 (en) | 2004-03-30 | 2005-11-24 | Rejuvenon Corporation | Method of reducing C-reactive protein using growth hormone secretagogues |
| ES2602789T3 (es) * | 2007-02-09 | 2017-02-22 | Ocera Therapeutics, Inc. | Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina |
-
2008
- 2008-02-08 KR KR1020097017491A patent/KR20090112720A/ko not_active Ceased
- 2008-02-08 CA CA002677813A patent/CA2677813A1/en not_active Abandoned
- 2008-02-08 JP JP2009549593A patent/JP2010518158A/ja active Pending
- 2008-02-08 EP EP08725389.4A patent/EP2134341B1/en not_active Not-in-force
- 2008-02-08 EA EA200970764A patent/EA200970764A1/ru unknown
- 2008-02-08 CN CN200880011801A patent/CN101686966A/zh active Pending
- 2008-02-08 WO PCT/US2008/001748 patent/WO2008100448A2/en not_active Ceased
- 2008-02-08 MX MX2009008561A patent/MX2009008561A/es not_active Application Discontinuation
- 2008-02-08 AU AU2008216789A patent/AU2008216789A1/en not_active Abandoned
- 2008-02-11 US US12/069,533 patent/US20080207640A1/en not_active Abandoned
- 2008-02-13 TW TW097104956A patent/TWI450719B/zh active
-
2009
- 2009-08-12 IL IL200367A patent/IL200367A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101686966A (zh) | 2010-03-31 |
| KR20090112720A (ko) | 2009-10-28 |
| US20080207640A1 (en) | 2008-08-28 |
| WO2008100448A2 (en) | 2008-08-21 |
| AU2008216789A1 (en) | 2008-08-21 |
| TW200914019A (en) | 2009-04-01 |
| WO2008100448A3 (en) | 2008-10-23 |
| EP2134341A2 (en) | 2009-12-23 |
| EP2134341B1 (en) | 2015-06-17 |
| JP2010518158A (ja) | 2010-05-27 |
| TWI450719B (zh) | 2014-09-01 |
| EP2134341A4 (en) | 2011-08-17 |
| IL200367A0 (en) | 2010-04-29 |
| EA200970764A1 (ru) | 2010-04-30 |
| CA2677813A1 (en) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008100448A3 (en) | Method of treating cell proliferative disorders using growth hormone secretagogues | |
| MX2009010378A (es) | Metodos para tratar o prevenir el vomito utilizando secretagogos de hormona de crecimiento. | |
| TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
| MX2020010151A (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn. | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| TN2012000248A1 (en) | Novel spiropiperidine compounds | |
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| MX2022001863A (es) | Metodos para tratar los tumores del estroma gastrointestinal. | |
| IN2014KN00948A (enExample) | ||
| MX360030B (es) | Metodos para tratar el trastorno bipolar. | |
| JO2885B1 (en) | Protein kinase inhibitors | |
| SA515360229B1 (ar) | مثبطات عامل التمايز والنمو 8 | |
| GEP20135933B (en) | Compounds as bradykinin b1 antagonists | |
| WO2012082718A3 (en) | 3-methanesulfonylpropionitrile for treating inflammation and pain | |
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| WO2010149578A3 (en) | Novel biphenyl and phenyl-pyridine amides | |
| MX2012002387A (es) | Aminas de triazol fusionadas como moduladores p2x7. | |
| WO2012078757A3 (en) | Combination for breast cancer therapy with hsp90 inhibitory compounds | |
| PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| PH12019501566B1 (en) | Amide compounds and use thereof | |
| IN2012DN02816A (enExample) | ||
| WO2010039920A3 (en) | Boldine compounds for promoting bone growth | |
| WO2010002835A3 (en) | Vinpocetine and eburnamonine derivatives for promoting bone growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |